>
Switch to:

PTC Therapeutics Piotroski F-Score

: 4 (As of Today)
View and export this data going back to 2013. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PTC Therapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for PTC Therapeutics's Piotroski F-Score or its related term are showing as below:

NAS:PTCT' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 5
Current: 4

2
5

During the past 10 years, the highest Piotroski F-Score of PTC Therapeutics was 5. The lowest was 2. And the median was 3.


PTC Therapeutics Piotroski F-Score Historical Data

The historical data trend for PTC Therapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 2.00 4.00 2.00

PTC Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 3.00 4.00 4.00

Competitive Comparison

For the Biotechnology subindustry, PTC Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

PTC Therapeutics Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep21) TTM:Last Year (Sep20) TTM:
Net Income was -74.354 + -128.642 + -118.37 + -133.624 = $-455.0 Mil.
Cash Flow from Operations was -64.366 + -100.157 + -31.145 + -51.19 = $-246.9 Mil.
Revenue was 118.864 + 117.942 + 116.676 + 138.743 = $492.2 Mil.
Gross Profit was 113.978 + 108.838 + 109.318 + 132.204 = $464.3 Mil.
Average Total Assets from the begining of this year (Sep20)
to the end of this year (Sep21) was
(2181.059 + 2208.278 + 2111.941 + 2058.669 + 2007.325) / 5 = $2113.4544 Mil.
Total Assets at the begining of this year (Sep20) was $2,181.1 Mil.
Long-Term Debt & Capital Lease Obligation was $376.5 Mil.
Total Current Assets was $1,011.1 Mil.
Total Current Liabilities was $465.3 Mil.
Net Income was -77.677 + -112.687 + -181.427 + -69.692 = $-441.5 Mil.

Revenue was 96.459 + 68.259 + 75.239 + 118.404 = $358.4 Mil.
Gross Profit was 92.917 + 64.174 + 69.935 + 113.737 = $340.8 Mil.
Average Total Assets from the begining of last year (Sep19)
to the end of last year (Sep20) was
(1641.486 + 1623.782 + 1545.592 + 1476.637 + 2181.059) / 5 = $1693.7112 Mil.
Total Assets at the begining of last year (Sep19) was $1,641.5 Mil.
Long-Term Debt & Capital Lease Obligation was $407.3 Mil.
Total Current Assets was $1,244.2 Mil.
Total Current Liabilities was $253.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PTC Therapeutics's current Net Income (TTM) was -455.0. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PTC Therapeutics's current Cash Flow from Operations (TTM) was -246.9. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep20)
=-454.99/2181.059
=-0.20860967

ROA (Last Year)=Net Income/Total Assets (Sep19)
=-441.483/1641.486
=-0.26895325

PTC Therapeutics's return on assets of this year was -0.20860967. PTC Therapeutics's return on assets of last year was -0.26895325. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PTC Therapeutics's current Net Income (TTM) was -455.0. PTC Therapeutics's current Cash Flow from Operations (TTM) was -246.9. ==> -246.9 > -455.0 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep20 to Sep21
=376.48/2113.4544
=0.17813491

Gearing (Last Year: Sep20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep19 to Sep20
=407.253/1693.7112
=0.24045008

PTC Therapeutics's gearing of this year was 0.17813491. PTC Therapeutics's gearing of last year was 0.24045008. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep21)=Total Current Assets/Total Current Liabilities
=1011.14/465.261
=2.17327479

Current Ratio (Last Year: Sep20)=Total Current Assets/Total Current Liabilities
=1244.174/253.822
=4.90175792

PTC Therapeutics's current ratio of this year was 2.17327479. PTC Therapeutics's current ratio of last year was 4.90175792. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PTC Therapeutics's number of shares in issue this year was 70.586. PTC Therapeutics's number of shares in issue last year was 67.641. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=464.338/492.225
=0.94334501

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=340.763/358.361
=0.95089309

PTC Therapeutics's gross margin of this year was 0.94334501. PTC Therapeutics's gross margin of last year was 0.95089309. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep20)
=492.225/2181.059
=0.22568165

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep19)
=358.361/1641.486
=0.21831499

PTC Therapeutics's asset turnover of this year was 0.22568165. PTC Therapeutics's asset turnover of last year was 0.21831499. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PTC Therapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

PTC Therapeutics  (NAS:PTCT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PTC Therapeutics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

PTC Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Southwell David P director C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven director PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter director, officer: Chief Executive Officer PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie officer: SVP, Finance & CAO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn director C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric officer: Chief Business Officer 550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B. officer: Chief Development Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael director 1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio officer: Chief Operating Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory officer: Chief Technical Ops Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma director C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B director 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)